Telix H1 2025 Results: Investor Webcast Notification
Telix today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025.
Telix Reports $204M Revenue, Up 63% YOY
Telix today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Austria
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by BASG for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enables healthcare providers in Austria to offer PSMA-PET imaging using a clinically validated gallium-based radiopharmaceutical.
Gozellix Receives Permanent HCPCS Code
Telix today announces that its next-generation PSMA PET imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code by the U.S. Centers for Medicare & Medicaid Services (CMS).
Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses
Telix today announces that its Telix Manufacturing Solutions (TMS) facility in Brussels South (Seneffe), Belgium, has produced its first Good Manufacturing Practice (GMP)-grade commercial radiopharmaceutical doses and delivered them to the AIRC hospital collaboration in Charleroi, Belgium.
Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Italy
Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Italy by the AIFA for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enables healthcare providers across Italy to offer PSMA-PET imaging using a clinically validated gallium-based radiopharmaceutical.
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Belgium
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by AFMPS for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enables healthcare providers in Belgium to offer PSMA-PET imaging using a clinically validated gallium-based radiopharmaceutical.
Telix Precision Medicine Announces AlFluor™ Radiochemistry Platform
Telix today announces it has launched a novel PET radiochemistry solution based on 18F-aluminium fluoride (AlF), named AlFluorTM.
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
Telix today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting being held in New Orleans, Louisiana (U.S.) from June 21 – 24.
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Greece
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Greek EOF for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer - a broad clinical label. This approval enhances the options available to healthcare providers across Greece for PSMA-PET imaging using a clinically-validated, gallium-based radiopharmaceutical.